Quarterly report [Sections 13 or 15(d)]

WARRANTS TO PURCHASE COMMON STOCK

v3.26.1
WARRANTS TO PURCHASE COMMON STOCK
 3 Months Ended
Mar. 31, 2026
Warrants To Purchase Common Stock  
WARRANTS TO PURCHASE COMMON STOCK

NOTE 14 – WARRANTS TO PURCHASE COMMON STOCK

 

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company at March 31, 2026:

 

Exercise     Number     Expiration  
Price     Outstanding     Date  
$ 0.001       615,025 (1)   December 2030  
$ 1,056.00       4,585     April 2029  
$ 1,056.00       2,782     April 2029  
$ 1,056.00       2,172     April 2029  
$ 1,056.00       10,884     April 2029  
$ 1,600.00       36     October 2028  
$ 2,720.00       5,758     December 2028  
$ 3,200.00       22     August 2028  
          641,264        
(1) Represents prefunded warrants.

 

During the three months ended March 31, 2025, warrants totaling 10,884 became exercisable, 5,758 became exercisable upon FDA acceptance of our NDA filing, and 1, with an exercise price of $1,056, $1,776 and $364,800, respectively, expired.